Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
The New Vaccine Surveillance Network: 25 years of active, population-based surveillance for pediatric infectious diseases in the United States.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Payne Daniel C, Weinberg Geoffrey A, Halasa Natasha B, Englund Janet A, Boom Julie A, Selvarangan Rangaraj, Michaels Marian G, Williams John V, Sahni Leila C, Klein Eileen J, Harrison Christopher J, Schuster Jennifer E, Schlaudecker Elizabeth P, Griffin Marie G, Edwards Kathryn M, Mirza Sara A, Moline Heidi L, Dawood Fatimah S, Parashar Umesh D, Staat Mary Allen, Szilagyi Peter G, NVSN Collaborators
Аннотация
BACKGROUND: In 1999, the Centers for Disease Control and Prevention (CDC) established the New Vaccine Surveillance Network (NVSN) as a multi-site pediatric infectious diseases active surveillance system.
METHODS: NVSN prospectively collects population-based clinical, epidemiologic, and laboratory information on children who seek medical care at hospitals, emergency departments, urgent care centers, and outpatient clinics with symptoms of acute respiratory infections (ARI) and acute gastroenteritis (AGE) in the United States.
RESULTS: These efforts have clearly established the significant burden of both ARI and AGE in US children, demonstrated the effectiveness of licensed pediatric vaccines, and helped guide their use. The surveillance platform also measures the real-world impact of preventive measures intended to avoid or ameliorate adverse child health outcomes within the US healthcare system. Furthermore, NVSN provides a platform for detecting and evaluating emerging infections (e.g. enterovirus D-68, SARS-CoV-2) and unexpected sequelae in children.
CONCLUSIONS: For 25 years NVSN has provided an evidence-based foundation for pediatric infectious disease policy decision-making through objective, empirical data. Sustained investment in disease surveillance guides the scientific principles and public health practices that prevent suffering and premature death, prepares us for new and existent pathogen threats, and enables wise economic decisions that improve the health of Americans.
METHODS: NVSN prospectively collects population-based clinical, epidemiologic, and laboratory information on children who seek medical care at hospitals, emergency departments, urgent care centers, and outpatient clinics with symptoms of acute respiratory infections (ARI) and acute gastroenteritis (AGE) in the United States.
RESULTS: These efforts have clearly established the significant burden of both ARI and AGE in US children, demonstrated the effectiveness of licensed pediatric vaccines, and helped guide their use. The surveillance platform also measures the real-world impact of preventive measures intended to avoid or ameliorate adverse child health outcomes within the US healthcare system. Furthermore, NVSN provides a platform for detecting and evaluating emerging infections (e.g. enterovirus D-68, SARS-CoV-2) and unexpected sequelae in children.
CONCLUSIONS: For 25 years NVSN has provided an evidence-based foundation for pediatric infectious disease policy decision-making through objective, empirical data. Sustained investment in disease surveillance guides the scientific principles and public health practices that prevent suffering and premature death, prepares us for new and existent pathogen threats, and enables wise economic decisions that improve the health of Americans.